Veradermics’ program in alopecia areata provides further evidence of the company’s commitment to finding solutions to common skin conditions that are overdue for clinical change. Alopecia areata, an autoimmune hair loss disease that affects one million adults and 200,000 children in the U.S., has a significant quality of life burden and is associated with depression and suicidal ideation. There are no FDA-approved topical treatments for alopecia areata.

Veradermics is developing VDAA as a first-in-class topical treatment that can be applied monthly for all severities of alopecia areata and is supported by more than 40 years of data. VDAA has decades of real-world safety and efficacy support in the published literature and should not require routine laboratory monitoring with use.